Muaiad Kittaneh, Senior Director at ICON, shared a post on LinkedIn:
“In Boston for Clinical Trials in Oncology East Coast 2026, where I’ll be speaking on:
Reimagining the oncology patient journey: From protocol design to real-time, decision-driven trials.
Oncology development is moving beyond traditional protocol execution. The opportunity now is to embed patient journey insights earlier, use integrated data more intelligently, and connect sponsors, CROs, diagnostic partners, sites, and investigators in ways that improve both trial speed and evidence quality.
A few themes I’m looking forward to discussing:
- Using EHR, genomics, biomarkers, MRD/ctDNA, and real-time feasibility to inform better trial decisions
- Enabling more precise enrollment and site activation strategies
- Designing trials that generate faster, more reliable, decision-grade evidence
- Building execution models that are more patient-centered, data-driven, and operationally realistic
Looking forward to representing Syneos Health and engaging with colleagues across oncology clinical development, operations, diagnostics, and patient advocacy.”
Other articles featuring Muaiad Kittaneh on OncoDaily.
